Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|6|1116-1116

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.6, 2015-06, pp. : 1116-1116

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1115-1115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical application of asparaginase activity levels following treatment with pegaspargase

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1102-1105

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reply to ‘Harms of Cognitive Behaviour Therapy Designed to Increase Activity Levels in Chronic Fatigue Syndrome’

By  

Psychotherapy and Psychosomatics, Vol. 80, Iss. 2, 2011-01 ,pp. : 112-112

Karger

Access to resources Recommend Favorite

Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 3, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

D-Dimer Levels in Combination with Clinical Risk Factors Can Effectively Predict Subsequent Thromboembolic Events in Patients with Atrial Fibrillation during Oral Anticoagulant Therapy

By  

Cardiology, Vol. 117, Iss. 1, 2010-09 ,pp. : 31-36

Karger

Access to resources Recommend Favorite